OrforglipronResearch, Evidence & Safety Profile

Orforglipron, sold under the brand name Foundayo in the United States, is an oral GLP-1 (glucagon-like peptide-1) receptor agonist developed by Eli Lilly and Company (Indianapolis, IN). The FDA approved Foundayo on April 1, 2026 for chronic weight management. It is the only FDA-approved oral GLP-1 medication for weight loss that can be taken at any time of day without food or water restrictions — a meaningful practical differentiator versus oral semaglutide (Rybelsus / oral Wegovy), which requires fasting administration in the morning with a small volume of water and a 30-minute wait before eating or drinking.

A common source of confusion: orforglipron is grouped with peptide GLP-1 agonists like semaglutide and tirzepatide in clinical and consumer discussion, but chemically it is not a peptide. Orforglipron is a small organic molecule designed to mimic GLP-1 activity at the receptor — it shares mechanism and effect with peptide GLP-1 agonists but not chemical class. This article includes orforglipron because the peptide and small-molecule GLP-1 agonists are increasingly used in the same treatment decisions, but the regulatory and stability differences (no cold-chain handling, no injection, no peptide-specific bioavailability problems) are practical and significant.

FDA approval was based on the Phase 3 ATTAIN clinical program, which enrolled more than 4,500 adults. In ATTAIN-1 — the pivotal trial in adults with obesity or overweight without diabetes (n=3,127) — adults who took the highest dose of orforglipron and remained on treatment lost an average of 12.4% of their body weight (approximately 27.3 lbs / 12.4 kg) versus placebo over 72 weeks. The companion ATTAIN-2 trial in adults with obesity and type 2 diabetes (n > 1,600) reported similarly meaningful weight reductions and improvements in HbA1c. A 65-and-older sub-analysis of ATTAIN-1 and ATTAIN-2 reported weight reductions of up to approximately 13% in older adults.

In May 2026, two additional clinical readouts examined the use of orforglipron as a maintenance therapy after high-dose injectable GLP-1 treatment. In one trial, adults who switched from high-dose injectable Wegovy (semaglutide) to daily oral Foundayo regained an average of about 0.9 kg (~2 lbs) over 12 months; in a parallel trial, adults who switched from high-dose injectable Zepbound (tirzepatide) to daily Foundayo regained approximately 5 kg (~11 lbs) over 12 months. A separate maintenance trial reported that reducing Zepbound to a lower 5 mg maintenance dose also preserved most of the weight reduction compared with full discontinuation. Together, these data begin to characterize how oral and lower-dose injectable strategies might be used to sustain weight loss after a high-dose induction phase.

Orforglipron is a small-molecule agonist of the GLP-1 receptor. It binds to and activates the same G protein-coupled receptor (GLP-1R) that peptide agonists like semaglutide, liraglutide, and the GLP-1 component of tirzepatide bind to, but achieves this activation with a non-peptide chemical scaffold.

• GLP-1 receptor activation in pancreas: Stimulates glucose-dependent insulin secretion. Because insulin release is gated on glucose, hypoglycemia risk is low in the absence of concomitant insulin or sulfonylurea therapy.
• GLP-1 receptor activation in central nervous system: Signals through hypothalamic and brainstem appetite circuits to reduce hunger and caloric intake. This is the dominant mechanism for weight loss.
• Gastric emptying delay: Slows the rate at which food leaves the stomach, contributing to early satiety and reduced post-meal glucose excursions.
• Glucagon suppression: Suppresses inappropriately elevated post-prandial glucagon secretion, contributing to improved glucose control.

The small-molecule chemistry is what enables the practical advantages over oral peptide GLP-1 agonists. Peptide drugs are typically degraded by gastric acid and proteases, and they cross intestinal membranes poorly. Oral semaglutide (Rybelsus) overcomes this by co-formulation with sodium N-(8-[2-hydroxybenzoyl]amino) caprylate (SNAC), a permeation enhancer — but this requires strict fasting administration in the morning with no food or other beverage for at least 30 minutes. Orforglipron, as a small molecule, is acid-stable and orally bioavailable without needing a permeation enhancer or fasting administration. This is why Foundayo can be taken at any time of day, with or without food, with or without water.

Compared with the peptide GLP-1 agonists, orforglipron does not have the dual GLP-1/GIP activity of tirzepatide, nor the triple GLP-1/GIP/glucagon activity of retatrutide. Its weight-loss efficacy in Phase 3 ATTAIN-1 (12.4%) is therefore comparable to single-target GLP-1 peptide agonists like semaglutide (14.9% in STEP-1) rather than to dual or triple agonists.

The Phase 3 ATTAIN clinical program is the basis for FDA approval. The following summarizes the published topline data; full peer-reviewed trial publications are landing in NEJM, JAMA, and Lancet through mid-to-late 2026.

ATTAIN-1 — Obesity Without Diabetes (Phase 3 pivotal, n=3,127, 72 weeks)

• Population: Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity; no type 2 diabetes.
• Primary endpoint: Mean percent body weight reduction at week 72.
• Topline result: Approximately 12.4% mean body weight reduction (about 27.3 lbs / 12.4 kg) on the highest evaluated dose versus placebo. Lower doses produced intermediate effects in a dose-response pattern.
• Responder rates: Majority of participants on the highest dose achieved at least a 5% body weight reduction; a substantial fraction achieved 10% or more.
• Secondary outcomes: Improvements in waist circumference, blood pressure, fasting glucose, and lipid markers consistent with the GLP-1 class.

ATTAIN-2 — Obesity With Type 2 Diabetes (Phase 3, n > 1,600, 72 weeks)

• Population: Adults with obesity or overweight and type 2 diabetes.
• Co-primary endpoints: Body weight reduction and HbA1c reduction at week 72.
• Topline result: Clinically meaningful weight reduction (lower in magnitude than ATTAIN-1, as is typical for the class in T2D populations) and meaningful HbA1c improvement on the higher orforglipron doses versus placebo.

Older-Adult Sub-Analysis (ATTAIN-1 + ATTAIN-2, age ≥ 65)

• Adults aged 65 and older achieved weight reductions of up to approximately 13% on the highest dose. Tolerability profile was broadly similar to the overall trial population, though older adults are generally more sensitive to GI adverse events and dehydration.

Maintenance-Switch Trials (May 2026 readouts)

Two trials examined whether oral orforglipron could be used to maintain weight loss achieved on high-dose injectable GLP-1 therapy. These addressed an emerging clinical question — once a patient has reached their target weight on injectable Wegovy or Zepbound, what is the best approach to sustain the result without continuing the highest dose indefinitely?

• Wegovy-to-Foundayo switch trial: Adults who transitioned from high-dose Wegovy (semaglutide) to daily oral Foundayo regained an average of approximately 0.9 kg (~2 lbs) over 12 months — a small fraction of their prior weight loss, suggesting orforglipron can effectively sustain semaglutide-induced weight reduction.
• Zepbound-to-Foundayo switch trial: Adults who transitioned from high-dose Zepbound (tirzepatide) to daily oral Foundayo regained an average of approximately 5 kg (~11 lbs) over 12 months. The larger regain compared with the semaglutide switch likely reflects tirzepatide's greater pharmacodynamic potency (dual GLP-1/GIP versus single GLP-1 mechanism), meaning a step down to a GLP-1-only oral agent leaves more weight-loss "headroom" unfilled.

A separate maintenance study reported that reducing Zepbound to a lower 5 mg maintenance dose also preserved most of the weight reduction relative to full discontinuation, suggesting that low-dose maintenance and oral switch are both viable options after a high-dose induction phase.

Class context

Orforglipron's 12.4% Phase 3 weight loss places it modestly below injectable semaglutide (14.9% in STEP-1), well below tirzepatide (up to 22.5% in SURMOUNT-1), and substantially below retatrutide (up to 28.7% in TRIUMPH-4). Its differentiated value rests on three practical features: it is oral, it has no food or water timing restrictions, and it does not require cold-chain storage or self-injection.

Orforglipron's safety profile is broadly consistent with the GLP-1 receptor agonist class. Common, expected, and serious adverse events to be aware of:

• Gastrointestinal adverse events (most common): Nausea, vomiting, diarrhea, and constipation. These are most frequent during dose titration and typically mild to moderate, but can be severe enough to prompt discontinuation in a subset of patients. The titration schedule is designed to minimize GI tolerability problems.
• Decreased appetite and early satiety: An intended effect, but can lead to inadequate nutrient and fluid intake if not actively managed — particularly protein intake during weight loss and adequate water intake to prevent dehydration.
• Hypoglycemia: Low risk as monotherapy. Risk increases substantially with concomitant insulin or sulfonylurea use; dose adjustment of those medications is often required when starting orforglipron.
• Pancreatitis: A class-wide rare adverse event. Severe, persistent abdominal pain — particularly if radiating to the back — requires prompt medical evaluation.
• Gallbladder events: Cholelithiasis and cholecystitis have been reported with GLP-1 agonists, particularly in the context of rapid weight loss.
• Acute kidney injury: Volume depletion from persistent vomiting or diarrhea can precipitate AKI, particularly in older adults or in those on diuretics, ACE inhibitors, or NSAIDs.
• Thyroid C-cell tumors (boxed warning, class): Rodent studies of GLP-1 agonists have shown thyroid C-cell tumors. The relevance to humans is uncertain, but orforglipron carries the class-wide contraindication in personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Diabetic retinopathy: Rapid improvement in glycemic control can transiently worsen pre-existing diabetic retinopathy. Patients with established retinopathy should have ophthalmologic follow-up.
• Suicidal ideation signal (class monitoring): The FDA continues post-marketing surveillance of suicidal ideation across the GLP-1 class. Patients and clinicians should monitor for mood changes during treatment.
• NAION (non-arteritic anterior ischemic optic neuropathy): A 2026 pharmacovigilance signal for the GLP-1 class is under active investigation. Sudden vision changes warrant prompt ophthalmologic evaluation.

Orforglipron is contraindicated in pregnancy and is not recommended during breastfeeding. Effective contraception is recommended during use and for at least one month after the last dose. As a chronic medication, ongoing monitoring of weight, blood pressure, glycemic control (in T2D), renal function, and any GI symptoms is standard practice.

Disclaimer: The following is reference information about the FDA-approved labeling. It is not a recommendation to self-administer, adjust doses, or modify a prescribed regimen. All dosing decisions are made by a prescribing clinician.

Foundayo is administered as once-daily oral tablets, with or without food, with or without water, at any time of day. The labeled titration schedule begins at a low starting dose to minimize GI adverse events and steps up at fixed intervals to a maintenance dose. The maintenance dose is individualized based on efficacy and tolerability, with dose-response observed across the labeled range in the Phase 3 ATTAIN program.

Practical considerations from the labeled use:

• Missed dose: If a dose is missed, it can be taken the same day if remembered; otherwise the next dose should be taken at the regular time the following day. Doses are not doubled to compensate.
• Concomitant medications: Patients on insulin or sulfonylureas should expect a dose reduction of those medications when starting orforglipron, given hypoglycemia risk. Patients on oral medications with narrow therapeutic windows (warfarin, levothyroxine, oral contraceptives) should review timing with their prescriber — although orforglipron's gastric emptying effect is more modest than injectable GLP-1 peptides, residual interactions are possible.
• Renal and hepatic impairment: Dose adjustments and clinical monitoring guidance in renal and hepatic impairment are in the FDA label.
• Discontinuation: Stopping orforglipron typically results in some weight regain over months. The May 2026 maintenance-switch data suggest that step-down strategies (low-dose injectable maintenance or transition to a different oral agent) may attenuate regain compared with abrupt full discontinuation.

Specific dose values and the labeled titration schedule are documented in the FDA-approved Foundayo prescribing information, which is the authoritative reference for clinical use.

The orforglipron development program represents the most advanced oral, non-peptide GLP-1 receptor agonist in the obesity and type 2 diabetes therapeutic landscape as of 2026.

• ATTAIN-1 (obesity, no diabetes, Phase 3, 72 weeks, n=3,127): Pivotal trial supporting FDA approval. Primary endpoint of mean percent body weight reduction met at the highest dose with an approximately 12.4% reduction versus placebo. Full peer-reviewed publication landing in NEJM in mid-2026.
• ATTAIN-2 (obesity with T2D, Phase 3, 72 weeks, n > 1,600): Co-primary endpoints of body weight reduction and HbA1c reduction met. Established the indication in type 2 diabetic populations.
• ATTAIN older-adult sub-analysis (n=ages ≥ 65 from ATTAIN-1 and ATTAIN-2): Up to approximately 13% weight reduction at the highest dose in adults 65 and older, with a tolerability profile broadly similar to the overall trial population.
• Maintenance-switch trials (May 2026 readouts): Adults switching from high-dose injectable Wegovy to daily oral Foundayo regained ~0.9 kg over 12 months; adults switching from high-dose Zepbound to Foundayo regained ~5 kg over 12 months. A parallel Zepbound 5 mg maintenance-dose trial showed comparable preservation of weight loss versus full discontinuation. These data are the first peer-reviewed evidence on how to sustain weight loss after a high-dose injectable induction phase.
• Cardiovascular outcomes: A dedicated cardiovascular outcomes trial for orforglipron is in planning or early execution. The semaglutide SELECT trial (2024) established cardiovascular benefit for a GLP-1 agonist in non-diabetic adults with obesity and prior cardiovascular disease; whether orforglipron's small-molecule chemistry produces an equivalent cardiovascular signal is a major open question.
• Other indications under investigation: Lilly is studying or expected to study orforglipron in metabolic dysfunction-associated steatohepatitis (MASH), obstructive sleep apnea, and other obesity-related conditions, mirroring the broader GLP-1 class development pattern.

Practically, the small-molecule, oral, no-restriction profile makes orforglipron the most logistically accessible FDA-approved GLP-1 weight-loss medication. Whether it captures market share at scale will depend on payer coverage, real-world tolerability, and how the maintenance-switch use case develops in the year following approval.

Orforglipron (Foundayo) is FDA-approved for chronic weight management as of April 1, 2026. It is a prescription medication available through licensed U.S. pharmacies with a valid prescription.

• United States: FDA-approved for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, dyslipidemia), as an adjunct to a reduced-calorie diet and increased physical activity. Available by prescription only. Schedule: non-controlled.
• European Union and other markets: Regulatory filings and approval timelines vary by region. Refer to Lilly's regulatory disclosures for current status outside the United States.
• Compounding status: Orforglipron is a small-molecule prescription medication and is not eligible for compounding under FDA 503A or 503B pathways in the way that semaglutide and tirzepatide briefly were while on the FDA drug shortage list. Foundayo has never been on the FDA drug shortage list. Any product marketed as compounded orforglipron, generic orforglipron, or research-grade orforglipron should be regarded as unauthorized and potentially unsafe.
• Insurance and access: As a newly approved branded chronic weight-management medication, payer coverage is variable. List price, manufacturer savings programs, and step-therapy requirements are addressed by Lilly and individual insurers; access patterns are still developing in the months following the April 2026 approval.
• Off-label use: Prescribers may use Foundayo off-label within their clinical judgment, but coverage and reimbursement are typically tied to the FDA-approved indication.